摘要
目的探讨国产多西紫杉醇(多帕菲,齐鲁制药)单用以及多帕菲+顺铂联合化疗方案对非小细胞肺的临床疗效和安全性,并以进口多西紫杉醇(泰索帝)+顺铂联合化疗方案作对照。方法患者随机分入多帕菲单用组(A组,41例):多帕菲40mg/m2i.v.qw×6,每8周为1周期;多帕菲+顺铂组(B组,40例):多帕菲75mg/m2i.v.d1+顺铂80mg/m2i.v.分3d用,每21d为1周期;泰索帝+顺铂组(C组,43例):泰索帝75mg/m2i.v.d1+顺铂80mg/m2i.v.分3d用,每21d为1周期。结果入组的124例中116例可评价疗效,A、B和C组有效率分别为17.95%、21.62%、25.00%。B和C组有效率相似。不良反应主要有中性粒细胞减少、贫血、粒细胞减少性发热、其他发热、脱发、恶心呕吐和乏力。C组中性粒细胞减少的发生率高于B组,两组间差异有显著性(P<0.05)。其余不良反应两组相似。结论国产多西紫杉醇(多帕菲)+顺铂与进口多西紫杉醇(泰索帝)+顺铂两联合化疗方案相似,对非小细胞肺癌有一定疗效,且毒性可耐受。
[Objective] To investigate prospectively the efficacy and safety of docetaxel and two docetaxel plus cisplatin regimens in patients suffered from non-small-cell lung cancer(NSCLC). [Methods] 124 patients suffered from NSCLC between January 2004 and March 2005 were randomly assigned to receive a docetaxel-based chemotherapy, i.e. single-agent docetaxel (Zhusheyong Duoxitasai) 40 mg/m^2 i.v. qwx6 every 8 weeks(A group, 41 cases); docetaxel (Zhusheyong Duoxitasai) 75 mg/m^2 i.v.dl plus cisplatin 80rag/m^2 i.v. every 3 weeks(B group, 40 cases); docetaxel (Taxotere) 75mg/m^2 i.v.dl plus cisplatin 80 mg/m^2 i.v. every 3 weeks (C group 43 ). [Results] 116 of 124 patients were evaluable for efficacy. Overall response rates of A, B and C were 17.95%, 21.62% and 25.00%, respectively. Response within B group was similar to within C group. The major toxicities were neutropenia, anemia, febrile neutropenia, fever, alopecia, nausea, vomiting and fatigue. Neutropenia was more common within C group than within B group (P 〈0.05). [Conclusion] Two docetaxel plus cisplatin regimens are effective and well-tolerated treatment in patients suffered from NSCLC.
出处
《中国医学工程》
2005年第6期622-625,共4页
China Medical Engineering
关键词
非小细胞肺癌
多西紫杉醇
顺铂
治疗
Non-small-cell lung cancer(NSCLC)
docetaxel
cisplatin
treatment